Why Clover Health Investments, Corp.’s (CLOV) Stock Is Up 12.66%
As of Friday, October 09, Clover Health Investments, Corp.’s CLOV share price has surged by 12.66%, which has investors questioning if this is right time to sell.Michael Rose
Stock Evaluator: Clover Health Investments, Corp. (CLOV)
Clover Health Investments, Corp. CLOV
$4.79
0.21
4.59%
October 9, 2026 4:00:00 PM
EST
Volume: 10,518,217
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Providers & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Clover Health Investments, Corp. provides medicare advantage plans in the United States. The company offers preferred provider organization and health maintenance organization plans to medicare-eligible individuals. It also operates Clover Assistant, a software platform for physicians to detect, identify, and manage chronic diseases. The company was founded in 2014 and is based in Wilmington, Delaware.
Commentary & Analysis
Why Clover Health Investments, Corp.’s (CLOV) Stock Is Down 7.06%
As of Tuesday, September 15, Clover Health Investments, Corp.’s CLOV share price has dipped by 7.06%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Clover Health Investments, Corp.’s (CLOV) Stock Is Up 8.18%
As of Thursday, September 10, Clover Health Investments, Corp.’s CLOV share price has surged by 8.18%, which has investors questioning if this is right time to sell.Michael Rose
Why Clover Health Investments, Corp.’s (CLOV) Stock Is Down 5.54%
As of Monday, August 17, Clover Health Investments, Corp.’s CLOV share price has dipped by 5.54%, which has investors questioning if this is right time to buy.Michael Rose
Is Clover Health Investments, Corp. (CLOV) Overvalued?
We dive into why Clover Health Investments, Corp. (CLOV) could be considered overvalued on 2026-08-05, based on AAII’s Value Score and Grade.Rosalio Madrigal
Financial Summary
| Share Statistics | CLOV | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,544.2 | $1,631.5 | 58% |
|
| Shares Out (Mil) | 545.4 | 77.7 | 89% |
|
| Institutional Ownership | 56.7% | 87.7% | 38% |
|
| Float (Mil) | 412.7 | 55.9 | 83% |
|
| Beta | 2.48 | 0.81 | 96% |
|
| Avg Daily Volume (000s) | 4,844 | 539 | 91% |
|
| Price Change (52-week) |
72.3% | 78.8% | 90% |
|
| Growth | CLOV | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 22.8% | 10.6% | 84% |
|
| Net Income (5yr) | 8.9% | (0.3%) | 53% |
|
| EPS (5yr) | 35.9% | 3.0% | 86 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (23.1%) | (17.3%) | 28% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | $0.010 | $0.140 | $0.150 | |
| Month Ago EPS | $0.010 | $0.140 | $0.150 | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | $0.000 | $0.090 | $0.100 | |
| Year/Year Chg | (80.0%) | (183.8%) | (225.7%) | |
| Financials | CLOV | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2,476 | $1,505 | 63% |
|
| Net Income (TTM) (Mil) | ($18) | $26 | 24% |
|
| EPS (TTM) | ($0.035) | $0.200 | 37% |
|
| Operating Cash Flow (TTM) (Mil) | $77 | $157 | 50% |
|
| Net Cash Flow (TTM) (Mil) | $10 | $2 | 57% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $374 | 0% |
|
| Enterprise Value (Q1) (Mil) | $2,330 | $2,284 | 51% |
|
| Valuation | CLOV | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.75 | 2.93 | 85% |
|
| P/E | na | 25.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | CLOV | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 18.5% | 27.6% | 19% |
|
| Net Margin | (0.7%) | 1.2% | 30% |
|
| ROA | (2.8%) | 2.1% | 33% |
|
| ROE | (5.1%) | 6.9% | 31% |
|
| Liabilities to Assets | 47.8% | 60.8% | 40% |
|
| F-Score | 4 | 5 | 33% |
|
Passing Stock Screens
As of 10/9/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Price-to-Sales Screen
Factors: Value, Growth
Research indicates that using price-to-sales ratios may lead to better investment results than price-to-book-value ratios or price-earnings ratios.
| Performance Since Inception: | 13.0% |
| +/- S&P 500: | +5.5 |
